Veterinary injectable steroid
Boldenone Undecylenate (Equipoise)
Boldenone undecylenate (Equipoise) is a veterinary injectable steroid; FDA's rule covers 25 or 50 mg per mL solutions for horses.1 The app's half-life is 14 days; none of the sources below gives a human half-life.
Boldenone Undecylenate (Equipoise) after one dose: 50% at ~14 days, 25% at 28 days, 12.5% at 42 days.
Drawn from the half-life in the app's model, ~14 days. The model's figures
- Compound
- Boldenone Undecylenate (Equipoise)
- Symbol
- EQ
- Family
- Other steroids
- Parts
- 16
- References
- 18
- Checked
- Last reviewed . Sources are listed below.
How Milligram users log it

3%The 20th most tracked compound in Milligram: of people who track compounds in Milligram logged Boldenone Undecylenate (Equipoise) in the last 90 days.
Schedule
Logged doses
Half of people logged between 65 and 200 mg per dose; the median was 100 mg.
Tracked alongside
The share of people logging Boldenone Undecylenate (Equipoise) who also logged each.
From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.
Overview
Sources in this part
Equipoise is the brand name that FDA's 2005 notice gives to a boldenone undecylenate injection for horses, and FDA's regulation for injectable boldenone describes a solution containing 25 or 50 mg of boldenone undecylenate per mL.2,1
The Federal Register notice, effective 25 November 2005, records that Fort Dodge Animal Health filed a supplement to NADA 34-705 for the veterinary prescription use, and that approval of the supplement "did not require review of additional safety or effectiveness data".2
The figures row above is the app's own, and the sources' figures sit beside it in the pharmacokinetics and dose tables below. The Moderate Evidence label is the app's grade and not a conclusion of the sources: among the records read from the Europe PMC queries of 16 November 2026, none reported a clinical trial of injected boldenone undecylenate in people. The human studies cited here gave boldenone by mouth and measured urine, the injected-ester trials cited here are in horses, ponies and bulls, broiler chicks were injected with boldenone (form not stated), and one cattle study is a histology survey.
How it works
The US Schedule III list covers "any substance meeting the definition of anabolic steroid as set forth in § 1300.01" and names boldenone (17β-hydroxyandrost-1,4-diene-3-one) among its substances, with "its salts, esters and ethers", all "unless specifically excepted or unless listed in another schedule"; the cited text does not address the veterinary product Equipoise.3
After oral boldenone in people, Schänzer and Donike, Biological Mass Spectrometry, 1992, identified boldenone and four metabolites in urine after glucuronidase treatment and reported that "More than 95% of metabolites are excreted as stable conjugates".4 Wu and colleagues, Journal of Pharmaceutical and Biomedical Analysis, 2015, reported that 17β-boldenone, 17α-boldenone and the metabolite they call BM1 "were excreted in urine in both free and glucuronic conjugated forms".5
In stallions given boldenone undecylenate or nandrolone decanoate, Squires and colleagues, Journal of Animal Science, 1982, reported "a depression in concentration of LH in all treatment groups".6 Garcia and colleagues, Theriogenology, 1987, reported no differences in mean plasma LH and FSH among groups of pony stallions given boldenone undecylenate, stanozolol or nothing.7 The sources cited here do not state a receptor mechanism, an aromatization rate or a conversion to estrogen for boldenone undecylenate.
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~14 days
- Bioavailability
- 95%
- Typical dose
- 100–500 mg/week
- Route
- IM
- Time to peak
- ~96 h
The app's figures for boldenone undecylenate are a half-life of 14 days (336 hours), a bioavailability of 95% and a time to peak of 96 hours. None of the cited sources gives a human half-life, bioavailability or time to peak for injected boldenone undecylenate, as the table shows.
| Measure | App figure | Source figure |
|---|---|---|
| Half-life | ~14 days | No human value. Weidolf and colleagues, 1988, obtained confirmatory evidence of boldenone sulfate in equine urine from 2 h to 42 days following a therapeutic intramuscular dose of Equipoise, and a second paper by the group obtained full-scan spectra of boldenone sulfate up to 17 days after a therapeutic dose to a horse; the records report urine detection times, give no half-life and do not state the number of horses or the dose.8,9 |
| Bioavailability | 95% | None of the cited sources gives a bioavailability figure for boldenone undecylenate. |
| Time to peak | ~96 h | None of the cited sources gives a time to peak. |
The chart below is an illustration from a model built on the app's half-life of 14 days (336 hours) and time to peak of 96 hours, not a measured curve. Its dose control is in mg on the app's own range, and no human source gives a dose of injected boldenone undecylenate. Its two intervals come from a rule and an animal trial, not from human use: every 3 weeks is the repeat interval in the US horse rule, and weekly is the schedule of one group of pony stallions.1,10
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: every 3 weeks (US horse rule)1, weekly (one pony group)10. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).
An illustration from a pharmacokinetic model using a half-life of 336 hours (14 days). It is not a measured level or a suggested dose.
Human studies
None of the records read from the Europe PMC queries of 16 November 2026 reported a trial of injected boldenone undecylenate in people. The two human studies cited here gave boldenone by mouth and measured urine, so they describe metabolism and do not involve the injected ester.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Schänzer and Donike, 19924 | Identification of urinary metabolites and excretion rates after oral boldenone. | Described as "man"; the number of people is not stated in the record. | Oral boldenone, doses from 11 to 80 mg; length not stated in the record. | Boldenone and four metabolites identified after glucuronidase hydrolysis; five more at low concentration; more than 95% of metabolites excreted as stable conjugates. |
| Wu and colleagues, 20155 | Urinary metabolism study with gas chromatography-tandem mass spectrometry; the record describes no control group. | 3 male and 3 female volunteers. | 30 mg of 17β-boldenone by mouth; collection length not stated in the record. | BM1 higher than 17β-boldenone for most subjects; 17α-boldenone in small amounts; the 30 mg did not influence urinary androsterone, etiocholanolone or testosterone/epitestosterone ratio; no differences in metabolic patterns between men and women. |
Sources in this part
Deeper analysis: oral boldenone in people (Schänzer and Donike, 1992; Wu and colleagues, 2015)
Wu and colleagues, who describe investigations of the excretion patterns of boldenone metabolites for both genders as insufficient, reported that 17α-boldenone, 17β-boldenone and BM1 "were present naturally in urine with low concentrations".5 The records name no funder, no author tie to a manufacturer and no limitations statement for either study. Both gave oral boldenone, so neither study measured blood levels, half-life or effects of the injected undecylenate.
Studies in horses, cattle and other animals
The trials of injected boldenone undecylenate cited here, and one cattle histology study, are in animals, and their results are not results in people.
| Study and year | Design | Animals | Dose and length | Main result |
|---|---|---|---|---|
| Squires and colleagues, 19826 | Controlled; control group given sesame oil. | 32 stallions in 4 groups. | Boldenone undecylenate 4.4 or 1.1 mg/kg, or nandrolone decanoate 1.1 mg/kg, every 3 weeks for 15 weeks. | Sperm motility, concentration and total sperm per ejaculate lowered by all anabolic steroid treatments; testis weights averaged 44.9% (4.4 mg/kg) and 61.6% (1.1 mg/kg) of controls and 40.1% with nandrolone; LH lowered in all treatment groups; erection, mounting and ejaculation measures not affected. |
| Blanchard and colleagues, 198310 | Randomised to 5 groups, including untreated controls and two stanozolol groups. | 50 mature pony stallions. | Boldenone undecylenate 1.1 mg/kg every 3 weeks for 5 treatments, or 0.55 mg/kg weekly for 13 treatments. | Weekly group: smaller scrotal width (P under 0.01), smaller combined testis weight and decreased daily sperm production against controls (P under 0.05). Every-3-weeks group: smaller scrotal width (P under 0.01), with combined testis weight and daily sperm production not different from controls. |
| Garcia and colleagues, 19877 | Randomised to the same 5 groups as Blanchard 1983. | 50 pony stallions aged 2 to 16 years. | The same two boldenone undecylenate schedules. | No differences in mean plasma LH and FSH among groups; mean plasma testosterone elevated over controls (P under 0.01) at 2, 8 and 9 weeks in the weekly stanozolol, every-3-weeks boldenone and weekly boldenone groups, and not different in the every-3-weeks stanozolol group; daily spermatid production per gram of testis and Leydig cell diameter lower in the weekly boldenone group than in controls (P under 0.05); no differences among groups in the percentage of stage 8 tubules or relative number of Leydig cells. |
| Squires and colleagues, 198511 | Follow-up of mares treated the year before; 4 groups including sesame oil controls. | 46 three-year-old mares. | Boldenone undecylenate 1.1 or 4.4 mg/kg, or nandrolone decanoate 1.1 mg/kg, every 3 weeks for 54 weeks (19 injections). | In the following breeding season, fewer mares in all steroid groups showed estrous behavior and estrus was shorter (both P under 0.05); abnormal sexual behavior seen during treatment continued for up to 6 months after it (P under 0.05); ovarian size, follicular development and tubular genitalia were adversely affected (P under 0.05) until about the middle of March, with no difference among groups after that; all mares ovulated by the end of the trial, with a similar interval to first ovulation; first-cycle pregnancy rates 83% untreated, 67% (1.1 mg/kg), 50% (4.4 mg/kg) and 42% (nandrolone), no test reported in the record. |
| Skelton and colleagues, 199112 | Dose groups of zero, low, medium and high. | 16 fillies from 7 to 11 months of age until 2 years. | Boldenone undecylenate 0.55, 1.1 or 2.2 mg/kg live weight; interval not stated in the record. | Ovarian activity (cross-sectional area, total ovulations, total follicles and large follicles) significantly reduced by steroid treatments; of fillies that ovulated in the first breeding season, the record states that "the age of first ovulation and the second breeding season was significantly delayed in the high dose group"; clitoral diameter greater in treated groups. |
| Wolfe and colleagues, 199113 | Two trials with untreated controls. | 17 bulls: 9 mature bulls (5 treated), 8 bull calves (4 treated). | Boldenone undecylenate 1.1 mg/kg every 21 days for 7 treatments (147 days). | Mature bulls: ejaculates of treated bulls held a higher percentage of abnormal spermatozoa, although the percentages with primary or secondary abnormalities did not differ. Calves: treated calves had a higher percentage of primary abnormalities, a higher average daily gain and needed 21 days longer for scrotal circumference to reach 30 cm. Semen quality was satisfactory for all bulls at each sampling day. |
Deeper analysis: the stallion and pony trials (Squires, 1982; Blanchard, 1983; Garcia, 1987)
Squires and colleagues grouped the lowered sperm measures as an effect of "all anabolic steroid treatments", which included nandrolone decanoate, so the boldenone groups are not separated in that sentence of the record.6 In the pony trials, Blanchard and colleagues report smaller scrotal width, smaller combined testis weight and decreased daily sperm production in the weekly boldenone group, and state that these three measures were not different between the controls and the group given stanozolol 0.55 mg/kg weekly.10 Garcia and colleagues report lower daily spermatid production per gram of testis and a smaller Leydig cell diameter in the weekly boldenone group.7 The records do not state whether the Blanchard and Garcia papers report the same animals, and name no funder or author tie and no limitations statement for these three trials; the record of the 1985 mare follow-up is cut off before its end.11
Deeper analysis: cattle histology (Groot and Biolatti, 2004)
Groot and Biolatti, 2004, examined 34 male veal calves and one finishing bull that had earlier tested positive for beta-boldenone in urine and were examined several weeks later; the record names no ester, route or dose and describes no control animals.14 They reported reduced testis development and degeneration of the germinal epithelium (70%), prostate hypersecretion and cyst formation (45%), and in some animals sampled periportal fibrosis, bile duct proliferation and sometimes necrosis in the liver; the bull showed absence of sperm production, and the record does not state what the 70% and 45% are percentages of.14 The authors concluded that beta-boldenone "may lead to degeneration of the germinal epithelium of the testis and hypersecretion and cyst formation in the prostate and bulbo-urethral gland, which alterations may heal in time".14
What tested samples contained
Sources in this part
Two product-testing studies from 2025 analysed anabolic steroid samples supplied by people who use them; neither is a clinical study of boldenone undecylenate.
Deeper analysis: samples from the Australian market (Craven and colleagues, 2025)
Craven and colleagues, Drug and Alcohol Review, 2025, had an independent forensic laboratory analyse 28 anonymously donated samples (16 injectable, 10 oral, 2 raw powders), reportedly purchased between 2022 and 2024, and 15 samples were mislabelled or mis-sold.15 Four injectables were labelled boldenone undecylenate at 200 mg/mL; three samples ranged from 101–206 mg/mL (mean 161 ± 54), and one boldenone sample was swapped for testosterone enanthate and propionate.15 The testing was facilitated and funded by PEDTest Australia, a private business led by CEO Alison Craven, who is also an author, and the paper states that the authors received no specific funding.15 The authors list as limitations that "The small sample size, while significant, may not be representative of the broader Australian AAS market" and that the study only covered products collected from 2022 to 2024.15
Magnolini and colleagues, Harm Reduction Journal, 2025, reported a pilot drug-checking service in Zurich in which 52 clients supplied 71 samples; 3 samples (4.2%) were labelled boldenone, and 52% of all samples were fake, either counterfeit (25%) or of substandard quality (27%), and the text gives no result for the boldenone samples on their own.16 Among the newly scheduled clients whose questionnaires were assessed (34 of the 52; recurring clients were excluded), boldenone was named in 39% when they listed current and past use of compounds, beside testosterone enanthate (61%) and testosterone blends (32%).16 The authors report no funding and list selection bias from recruitment, social desirability bias and a small sample as limitations of the pilot.16
Doses reported in studies and rules
The app's typical dose range is 100 to 500 mg a week. None of the cited sources reports a dose of injected boldenone undecylenate in people; the doses below are from a veterinary rule, animal trials and the two oral human studies.
| Source | Dose | Frequency | Length |
|---|---|---|---|
| US rule for horses1 | 0.5 mg per pound body weight by intramuscular injection | May be repeated at 3-week intervals | Not stated |
| Squires and colleagues, 1982, stallions6 | 1.1 or 4.4 mg/kg | Every 3 weeks | 15 weeks |
| Blanchard and colleagues, 1983, pony stallions10 | 1.1 mg/kg, or 0.55 mg/kg | Every 3 weeks, or weekly | 5 treatments, or 13 treatments |
| Squires and colleagues, 1985, mares11 | 1.1 or 4.4 mg/kg | Every 3 weeks | 54 weeks, 19 injections |
| Wolfe and colleagues, 1991, bulls13 | 1.1 mg/kg | Every 21 days | 7 treatments, 147 days |
| Schänzer and Donike, 1992, people, oral4 | 11 to 80 mg of boldenone | Not stated | Not stated |
| Wu and colleagues, 2015, volunteers, oral5 | 30 mg of 17β-boldenone | Not stated | Not stated |
Side effects reported
The records of the two human studies report no adverse event data. The animal findings are in the table above: lowered sperm measures and testis weights in stallions and ponies, fewer mares in estrus and shorter estrus, abnormal sexual behavior up to 6 months after treatment, first-cycle pregnancy rates of 67%, 50% and 42% against 83% untreated (no test reported in the record), a delay in the age of first ovulation in the high dose group of fillies, larger clitoral diameter in treated fillies, and more abnormal spermatozoa in bulls.6,10,11,12,13
Elmajdoub and colleagues, Journal of Food and Drug Analysis, 2016, gave 12 broiler chicks a single intramuscular injection of boldenone (form not stated) at 5 mg/kg and 12 chicks sesame oil.17 The boldenone group had higher erythrocyte count, hemoglobin and hematocrit, higher alkaline phosphatase, AST, ALT, urea and creatinine, leukopenia and lymphopenia (lower white cell and lymphocyte counts) with granulocytosis (higher granulocyte counts), lower mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration, higher total protein, globulins, cholesterol, triacylglycerols and glucose, lower albumin and albumin/globulin ratio, degenerative changes in liver and kidney tissue, and, in breast muscle, higher pH and higher microbial counts (p under 0.05 as reported for the blood measures).17 The PubMed record names no funder, and the authors write that the data "may discourage the use of boldenone as a growth promoter in broilers".17
Bloodwork and markers
The app lists total testosterone, free testosterone, estradiol, hematocrit, lipids and PSA as markers. Among the cited sources, broiler chicks injected with boldenone (form not stated) had higher hematocrit, cholesterol and triacylglycerols, plasma testosterone was reported elevated over controls in a pony trial, and LH was reported lowered in one stallion trial and unchanged in another.17,7,6 In six volunteers given 30 mg of oral 17β-boldenone, the urinary testosterone/epitestosterone ratio was not influenced.5 None of the cited sources reports estradiol, free testosterone or PSA after boldenone undecylenate.
Regulatory and anti-doping status
FDA's rule for injectable boldenone lists one indication, in horses: "As an aid for treating debilitated horses when an improvement in weight, hair coat, or general physical condition is desired".1 It adds the limitation "Do not administer to horses intended for human consumption" and states that "Federal law restricts this drug to use by or on the order of a licensed veterinarian".1 The cited sources include no approval for use of boldenone undecylenate in people.
The DEA's Schedule III list in 21 CFR 1308.13 includes boldenone among its anabolic steroids, with its salts, esters and ethers, unless specifically excepted or listed in another schedule; the cited text does not address the veterinary product Equipoise.3 WADA's 2026 Prohibited List places boldenone in S1.1, anabolic androgenic steroids when administered exogenously, in the class S1 anabolic agents.18 The list adds "and other substances with a similar chemical structure or similar biological effect(s) including their esters", and the class is prohibited at all times, in and out of competition, with every substance in it a non-Specified Substance.18
What is not known
The cited sources give no human half-life, bioavailability, time to peak or time to steady state for injected boldenone undecylenate, so the app's 14 days, 95% and 96 hours are not backed by them. They contain no controlled trial of its effects in people, no human adverse event data and no dose of injected boldenone undecylenate in people. The animal trials differ in species, dose and schedule, and their results (for example on LH) do not agree. The product-testing studies were small, with boldenone in 4 of 28 samples in the Australian study and 3 of 71 in the Zurich pilot.
Frequently asked questions
What is the half-life of Equipoise?
Is Equipoise banned by WADA?
WADA's 2026 Prohibited List names boldenone in S1.1, anabolic androgenic steroids when administered exogenously, prohibited at all times, in and out of competition.18
Is Equipoise a controlled substance?
The DEA's Schedule III list in 21 CFR 1308.13 includes boldenone among its anabolic steroids, with its salts, esters and ethers, unless specifically excepted or listed in another schedule; the cited text does not address the veterinary product Equipoise.3
Is Equipoise FDA approved?
What is Equipoise used for in veterinary medicine?
FDA's rule gives one indication, in horses: "As an aid for treating debilitated horses when an improvement in weight, hair coat, or general physical condition is desired".1
How long is boldenone detectable in urine?
In horse urine after a therapeutic intramuscular dose of Equipoise, boldenone sulfate was confirmed from 2 h to 42 days, and a second paper by the group obtained full-scan spectra of boldenone sulfate up to 17 days after a therapeutic dose to a horse; the records do not state the number of horses or the dose.8,9 The cited sources give no detection time for people.
What did animal trials of boldenone undecylenate report on testosterone, LH and fertility?
In 32 stallions in four groups (boldenone undecylenate 4.4 or 1.1 mg/kg, nandrolone decanoate 1.1 mg/kg, or sesame oil) given every 3 weeks for 15 weeks, LH was lowered and sperm measures and testis weights were reduced across all steroid groups.6 In 50 pony stallions (boldenone 1.1 mg/kg every 3 weeks or 0.55 mg/kg weekly, stanozolol, or none), plasma testosterone was elevated over controls (P under 0.01) in both boldenone groups and the weekly stanozolol group, and LH and FSH did not differ among groups.7
Are boldenone undecylenate products from unregulated sources what the label says?
In an Australian analysis of 28 donated anabolic steroid samples, 15 were mislabelled or mis-sold, and four injectables labelled boldenone undecylenate at 200 mg/mL included one swapped for testosterone enanthate and propionate and three quantified at 101–206 mg/mL.15
Guides, tools and comparisons
- Equipoise dosageA guide that answers a question on this compound.
- Calculator for EquipoiseA calculator set up for this compound.
- Previous in Other steroids: DianabolThe compound before this one in the class.
- Next in Other steroids: Fluoxymesterone (Halotestin)The compound after this one in the class.
References
- US Food and Drug Administration. 21 CFR 522.204 Boldenone (implantation or injectable dosage form new animal drugs). Electronic Code of Federal Regulations, 2026. 21 CFR 522.204
- US Food and Drug Administration. Implantation or Injectable Dosage Form New Animal Drugs; Boldenone. Federal Register 2005 (FR Doc. 05-23295). Federal Register 2005
- US Drug Enforcement Administration. 21 CFR 1308.13 Schedule III. Electronic Code of Federal Regulations, 2026. 21 CFR 1308.13
- Schänzer W, Donike M. Metabolism of boldenone in man: gas chromatographic/mass spectrometric identification of urinary excreted metabolites and determination of excretion rates. Biol Mass Spectrom 1992. PMID 1591280
- Wu X, et al. Metabolism study of boldenone in human urine by gas chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2015. PMID 26319750
- Squires EL, et al. Effect of anabolic steroids on reproductive function of young stallions. J Anim Sci 1982. PMID 7085517
- Garcia MC, et al. The effects of stanozolol and boldenone undecylenate on plasma testosterone and gonadotropins and on testis histology in pony stallions. Theriogenology 1987. PMID 16726297
- Weidolf LO, Chichila TM, Henion JD. Screening, confirmation and quantification of boldenone sulfate in equine urine after administration of boldenone undecylenate (Equipoise). J Chromatogr 1988. PMID 3235575
- Weidolf LO, Lee ED, Henion JD. Determination of boldenone sulfoconjugate and related steroid sulfates in equine urine by high-performance liquid chromatography/tandem mass spectrometry. Biomed Environ Mass Spectrom 1988. PMID 3365498
- Blanchard TL, et al. The effects of stanozolol and boldenone undecylenate on scrotal width, testis weight, and sperm production in pony stallions. Theriogenology 1983. PMID 16725839
- Squires EL, et al. Fertility of young mares after long-term anabolic steroid treatment. J Am Vet Med Assoc 1985. PMID 3988591
- Skelton KV, et al. Ovarian activity in fillies treated with anabolic steroids prior to the onset of puberty. J Reprod Fertil Suppl 1991. PMID 1795278
- Wolfe DF, et al. Effects of the anabolic steroid, boldenone undecylenate, on certain reproductive parameters in bulls. Theriogenology 1991. PMID 16726958
- Groot MJ, Biolatti B. Histopathological effects of boldenone in cattle. J Vet Med A Physiol Pathol Clin Med 2004. PMID 15153074
- Craven A, et al. Lead Astray? The Hidden Contaminants in Australian Anabolic-Androgenic Steroid Market and Their Potential Health Impact. Drug Alcohol Rev 2025. PMC12405805
- Magnolini R, et al. Evaluation of implementing drug checking services for anabolic androgenic steroids in Switzerland: a pilot study. Harm Reduct J 2025. PMC12147309
- Elmajdoub A, et al. Evaluation of boldenone as a growth promoter in broilers: safety and meat quality aspects. J Food Drug Anal 2016. PMID 28911580
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA 2026 list